Intrathecal baclofen for management of spastic cerebral palsy: Multicenter trial

Richard Gilmartin, Derek Bruce, Bruce B. Storrs, Ira Richmond Abbott, III, Linda Krach, John Ward, Karen Bloom, William H. Brooks, Dennis L. Johnson, Joseph R. Madsen, John F. McLaughlin, Joseph Nadell

Research output: Contribution to journalArticle

181 Citations (Scopus)

Abstract

Intrathecal baclofen infusion has demonstrated effectiveness in decreasing spasticity of spinal origin. Oral antispasticity medication is minimally effective or not well tolerated in cerebral palsy. This study assessed the effectiveness of intrathecal baclofen in reducing spasticity in cerebral palsy. Candidates were screened by randomized, double-blind, intrathecal injections of baclofen and placebo. Responders were defined as those who experienced an average reduction of 1.0 in the lower extremities on the Ashworth Scale for spasticity. Responders received intrathecal baclofen via the SynchroMed System and were followed for up to 43 months. Fifty-one patients completed screening and 44 entered open-label trials. Lower- extremity spasticity decreased from an average baseline score of 3.64 to 1.90 at 39 months. A decrease in upper-extremity spasticity was evidenced over the same study period. Forty-two patients reported adverse events. Most common reports were hypotonia, seizures (no new onset), somnolence, and nausea or vomiting. Fifty-nine percent of the patients experienced procedural or system-related events. Spasticity in patients with cerebral palsy can be treated effectively by continuous intrathecal baclofen. Adverse events, although common, were manageable.

Original languageEnglish (US)
Pages (from-to)71-77
Number of pages7
JournalJournal of Child Neurology
Volume15
Issue number2
StatePublished - Feb 2000
Externally publishedYes

Fingerprint

Baclofen
Cerebral Palsy
Multicenter Studies
Lower Extremity
Spinal Injections
Muscle Hypotonia
Upper Extremity
Nausea
Vomiting
Seizures
Placebos

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

Gilmartin, R., Bruce, D., Storrs, B. B., Abbott, III, I. R., Krach, L., Ward, J., ... Nadell, J. (2000). Intrathecal baclofen for management of spastic cerebral palsy: Multicenter trial. Journal of Child Neurology, 15(2), 71-77.

Intrathecal baclofen for management of spastic cerebral palsy : Multicenter trial. / Gilmartin, Richard; Bruce, Derek; Storrs, Bruce B.; Abbott, III, Ira Richmond; Krach, Linda; Ward, John; Bloom, Karen; Brooks, William H.; Johnson, Dennis L.; Madsen, Joseph R.; McLaughlin, John F.; Nadell, Joseph.

In: Journal of Child Neurology, Vol. 15, No. 2, 02.2000, p. 71-77.

Research output: Contribution to journalArticle

Gilmartin, R, Bruce, D, Storrs, BB, Abbott, III, IR, Krach, L, Ward, J, Bloom, K, Brooks, WH, Johnson, DL, Madsen, JR, McLaughlin, JF & Nadell, J 2000, 'Intrathecal baclofen for management of spastic cerebral palsy: Multicenter trial', Journal of Child Neurology, vol. 15, no. 2, pp. 71-77.
Gilmartin, Richard ; Bruce, Derek ; Storrs, Bruce B. ; Abbott, III, Ira Richmond ; Krach, Linda ; Ward, John ; Bloom, Karen ; Brooks, William H. ; Johnson, Dennis L. ; Madsen, Joseph R. ; McLaughlin, John F. ; Nadell, Joseph. / Intrathecal baclofen for management of spastic cerebral palsy : Multicenter trial. In: Journal of Child Neurology. 2000 ; Vol. 15, No. 2. pp. 71-77.
@article{97beee6d9a79445580ff74cc560d3c40,
title = "Intrathecal baclofen for management of spastic cerebral palsy: Multicenter trial",
abstract = "Intrathecal baclofen infusion has demonstrated effectiveness in decreasing spasticity of spinal origin. Oral antispasticity medication is minimally effective or not well tolerated in cerebral palsy. This study assessed the effectiveness of intrathecal baclofen in reducing spasticity in cerebral palsy. Candidates were screened by randomized, double-blind, intrathecal injections of baclofen and placebo. Responders were defined as those who experienced an average reduction of 1.0 in the lower extremities on the Ashworth Scale for spasticity. Responders received intrathecal baclofen via the SynchroMed System and were followed for up to 43 months. Fifty-one patients completed screening and 44 entered open-label trials. Lower- extremity spasticity decreased from an average baseline score of 3.64 to 1.90 at 39 months. A decrease in upper-extremity spasticity was evidenced over the same study period. Forty-two patients reported adverse events. Most common reports were hypotonia, seizures (no new onset), somnolence, and nausea or vomiting. Fifty-nine percent of the patients experienced procedural or system-related events. Spasticity in patients with cerebral palsy can be treated effectively by continuous intrathecal baclofen. Adverse events, although common, were manageable.",
author = "Richard Gilmartin and Derek Bruce and Storrs, {Bruce B.} and {Abbott, III}, {Ira Richmond} and Linda Krach and John Ward and Karen Bloom and Brooks, {William H.} and Johnson, {Dennis L.} and Madsen, {Joseph R.} and McLaughlin, {John F.} and Joseph Nadell",
year = "2000",
month = "2",
language = "English (US)",
volume = "15",
pages = "71--77",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Intrathecal baclofen for management of spastic cerebral palsy

T2 - Multicenter trial

AU - Gilmartin, Richard

AU - Bruce, Derek

AU - Storrs, Bruce B.

AU - Abbott, III, Ira Richmond

AU - Krach, Linda

AU - Ward, John

AU - Bloom, Karen

AU - Brooks, William H.

AU - Johnson, Dennis L.

AU - Madsen, Joseph R.

AU - McLaughlin, John F.

AU - Nadell, Joseph

PY - 2000/2

Y1 - 2000/2

N2 - Intrathecal baclofen infusion has demonstrated effectiveness in decreasing spasticity of spinal origin. Oral antispasticity medication is minimally effective or not well tolerated in cerebral palsy. This study assessed the effectiveness of intrathecal baclofen in reducing spasticity in cerebral palsy. Candidates were screened by randomized, double-blind, intrathecal injections of baclofen and placebo. Responders were defined as those who experienced an average reduction of 1.0 in the lower extremities on the Ashworth Scale for spasticity. Responders received intrathecal baclofen via the SynchroMed System and were followed for up to 43 months. Fifty-one patients completed screening and 44 entered open-label trials. Lower- extremity spasticity decreased from an average baseline score of 3.64 to 1.90 at 39 months. A decrease in upper-extremity spasticity was evidenced over the same study period. Forty-two patients reported adverse events. Most common reports were hypotonia, seizures (no new onset), somnolence, and nausea or vomiting. Fifty-nine percent of the patients experienced procedural or system-related events. Spasticity in patients with cerebral palsy can be treated effectively by continuous intrathecal baclofen. Adverse events, although common, were manageable.

AB - Intrathecal baclofen infusion has demonstrated effectiveness in decreasing spasticity of spinal origin. Oral antispasticity medication is minimally effective or not well tolerated in cerebral palsy. This study assessed the effectiveness of intrathecal baclofen in reducing spasticity in cerebral palsy. Candidates were screened by randomized, double-blind, intrathecal injections of baclofen and placebo. Responders were defined as those who experienced an average reduction of 1.0 in the lower extremities on the Ashworth Scale for spasticity. Responders received intrathecal baclofen via the SynchroMed System and were followed for up to 43 months. Fifty-one patients completed screening and 44 entered open-label trials. Lower- extremity spasticity decreased from an average baseline score of 3.64 to 1.90 at 39 months. A decrease in upper-extremity spasticity was evidenced over the same study period. Forty-two patients reported adverse events. Most common reports were hypotonia, seizures (no new onset), somnolence, and nausea or vomiting. Fifty-nine percent of the patients experienced procedural or system-related events. Spasticity in patients with cerebral palsy can be treated effectively by continuous intrathecal baclofen. Adverse events, although common, were manageable.

UR - http://www.scopus.com/inward/record.url?scp=12944257419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12944257419&partnerID=8YFLogxK

M3 - Article

C2 - 10695888

AN - SCOPUS:12944257419

VL - 15

SP - 71

EP - 77

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

IS - 2

ER -